PepsiCo Puts a Healthcare CEO on Its Board, Right as Healthcare Threatens Its Snacks

PepsiCo's board just got a little more healthcare. On Thursday, the company said it had elected Joaquin Duato — the chairman and CEO of Johnson & Johnson — as an independent director, effective December 1, with a seat on the Audit Committee. Chairman Ramon Laguarta framed the pick around Duato's "key role in driving strategic transformation, portfolio optimization and innovation" over three decades at J&J.

By itself, that's a one-day governance item. One outside director, no matter how decorated, does not move a profit and loss statement. But it's worth noticing where this announcement landed: PepsiCo shares are sitting within a dollar of their 52-week low of $132.93, down roughly 7% on the year, and yielding a hefty 4.3% as they wait for a turnaround that keeps slipping.

That's where the appointment gets interesting, in a dry sort of way. Duato doesn't bring snack expertise. He runs the largest healthcare company on the planet — and healthcare is now the industry posing the biggest structural threat to PepsiCo's snack business. The GLP-1 weight-loss drugs belong to Duato's world, and they're the reason the company's core franchise is struggling.

The threat isn't speculative anymore. Per PwC analysis of Numerator data, GLP-1 usage reached 21% of U.S. households by May 2026, up from 9% in early 2025, and those patients demonstrably buy fewer sweet and salty snacks. That matters enormously because PepsiCo's food brands — Doritos, Lay's, Ruffles, PopCorners — generate roughly 58% of annual revenue.

The numbers already show the strain. North American food volumes have fallen in four of the last six quarters; they were flat in the second quarter after climbing back to about 2% growth in the first. Crucially, price cuts of up to 15% on Lay's, Doritos, Cheetos and Tostitos did not bring volume back. North America beverage volume fell 4% in the quarter, against 4% growth for Coca-Cola in the region.

So a board appointment here reads less as a catalyst and more as a signal about emphasis. When a consumer staple under this kind of pressure goes looking for a director, it wants someone who has run a giant, heavily regulated, slow-moving global business and who understands portfolio reshuffling. Duato checks every box: before the corner office he ran J&J's pharmaceuticals and consumer-health sectors, and his whole career has been spent across businesses like the ones PepsiCo keeps debating whether to keep. Elliott Investment Management, holding a stake of roughly $4 billion, has been pushing the company to reinvigorate its soda business and explore selling non-core food assets — the kind of conversation a health-and-portfolio-savvy board is well placed to have.

Don't buy the stock on the board seat. The valuation case stands or falls on the volume problem, and at a 4.3% yield near a 52-week low the market is already pricing in a lot of doubt about a name that used to carry a defensive premium. The dividend is still covered — free cash flow of about $9.3 billion over the trailing twelve months, up 31% year over year, easily funds the payout. But a covered dividend only helps if the snack volumes stop their slide.

Duato arriving from healthcare is a reminder of that, not a solution to it. The question his appointment surfaces is the old, simple one: can PepsiCo get Americans snacking at autopilot levels again when the prices and the drugs are both pointing the other way? Watch the quarterly food volumes, not the board minutes.